CA2964520C - A19-144, a2-73 and certain anticholinesterase inhibitor compositions and method for anti-seizure therapy - Google Patents
A19-144, a2-73 and certain anticholinesterase inhibitor compositions and method for anti-seizure therapy Download PDFInfo
- Publication number
- CA2964520C CA2964520C CA2964520A CA2964520A CA2964520C CA 2964520 C CA2964520 C CA 2964520C CA 2964520 A CA2964520 A CA 2964520A CA 2964520 A CA2964520 A CA 2964520A CA 2964520 C CA2964520 C CA 2964520C
- Authority
- CA
- Canada
- Prior art keywords
- dosage form
- administration
- less
- aed
- day
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/14—Radicals substituted by nitrogen atoms not forming part of a nitro radical
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462065833P | 2014-10-20 | 2014-10-20 | |
| US62/065,833 | 2014-10-20 | ||
| PCT/US2015/056172 WO2016064711A1 (en) | 2014-10-20 | 2015-10-19 | A 19-144, a2-73 and certain anticholinesterase inhibitor compositions and method for anti-seizure therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2964520A1 CA2964520A1 (en) | 2016-04-28 |
| CA2964520C true CA2964520C (en) | 2023-09-26 |
Family
ID=55761357
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2964520A Active CA2964520C (en) | 2014-10-20 | 2015-10-19 | A19-144, a2-73 and certain anticholinesterase inhibitor compositions and method for anti-seizure therapy |
Country Status (5)
| Country | Link |
|---|---|
| US (4) | US10441563B2 (https=) |
| EP (1) | EP3209289A4 (https=) |
| JP (2) | JP2017531043A (https=) |
| CA (1) | CA2964520C (https=) |
| WO (1) | WO2016064711A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11337953B2 (en) * | 2016-07-27 | 2022-05-24 | Anavex Life Sciences Corp. | A2-73 as a therapeutic for insomnia, anxiety, and agitation |
| CA3083770A1 (en) | 2017-11-28 | 2019-06-06 | Anavex Life Sciences Corp. | Sigma-1 receptor agonist systolic blood pressure therapy |
| EP3794345B1 (en) | 2018-05-18 | 2025-02-26 | Anavex Life Sciences Corp. | Optimized sigma-1 agonist method of responder selection and treatment |
| EP3883546A1 (en) | 2018-11-21 | 2021-09-29 | Rosemont Pharmaceuticals Ltd | Oral topiramate suspension formulations with extended shelf stability and enhanced bioavailability |
| US11194591B2 (en) | 2019-01-23 | 2021-12-07 | Salesforce.Com, Inc. | Scalable software resource loader |
| US10802944B2 (en) | 2019-01-23 | 2020-10-13 | Salesforce.Com, Inc. | Dynamically maintaining alarm thresholds for software application performance management |
| US10747551B2 (en) | 2019-01-23 | 2020-08-18 | Salesforce.Com, Inc. | Software application optimization |
| US10922062B2 (en) | 2019-04-15 | 2021-02-16 | Salesforce.Com, Inc. | Software application optimization |
| US10922095B2 (en) | 2019-04-15 | 2021-02-16 | Salesforce.Com, Inc. | Software application performance regression analysis |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GR1002616B (el) * | 1996-02-21 | 1997-02-20 | Συνθεση και μεθοδος συνθεσης μοριου: τετραυδρο-ν,ν-διμεθυλο-2,2-διφαινυλο-3-φουρανομεθαναμινης (αε 37), αντισπασμωδικης, αντικαταθλιπτικης και νοοτροπικης δρασης. | |
| US20060252745A1 (en) * | 2005-05-06 | 2006-11-09 | Almeida Jose L D | Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use |
| EP1928437A2 (en) | 2005-08-26 | 2008-06-11 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
| GR1005865B (el) | 2007-01-17 | 2008-04-07 | Anavex Life Sciences Corp. | Νεοι συνδετες των σιγμα υποδοχεων με αντι-αποπτωτικες και/η προ-αποπτωτικες ιδιοτητες επι των κυτταρικων βιοχημικων μηχανισμων, με νευρο-προστατευτικη, αντικαρκινικη, αντι-μεταστατικη και αντι- αντι-(χρονιο)φλεγμονικη δραση. |
| US20100297181A1 (en) | 2007-12-26 | 2010-11-25 | Eisai R&D Management Co., Ltd. | AMPA Receptor Antagonists for Epilepsy, Mental Disorders or Deficits in Sensory Organ |
| GR1007686B (el) * | 2011-07-08 | 2012-09-12 | Αλεξανδρος Δημητριου Βαμβακιδης | Συνθεση των (+) και (-) 1-(5,5-διφαινυλοτετραϋδροφουραν-3-υλ)-ν,ν-διμεθυλομεθυλαμινης, (+) και (-) 1-(2,2-διφαινυλοτετραϋδροφουραν-3-υλ)-ν,ν-διμεθυλομεθυλαμινης και (+) και (-) 1-(2,2-διφαινυλοτετραϋδροφουραν-3-υλ)-ν-μεθυλομεθυλαμινης |
| GR1008233B (el) * | 2013-03-28 | 2014-06-23 | Αλεξανδρος Δημητριου Βαμβακιδης | Βελτιωση και θεραπευτικη αξιοποιηση της συμπτωματικης αντιμετωπισης της ασθενειας του alzheimer με rivastigmine, galantamine ή donepezil, δια επιλεγμενων αμινοτετραϋδροφουρανιων που δρουν σαν μικτοι σιγμα-1/ μουσκαρινικοι προσδετες |
-
2015
- 2015-10-19 CA CA2964520A patent/CA2964520C/en active Active
- 2015-10-19 JP JP2017539524A patent/JP2017531043A/ja active Pending
- 2015-10-19 US US15/571,877 patent/US10441563B2/en active Active
- 2015-10-19 EP EP15852696.2A patent/EP3209289A4/en active Pending
- 2015-10-19 WO PCT/US2015/056172 patent/WO2016064711A1/en not_active Ceased
-
2019
- 2019-10-14 US US16/601,323 patent/US10813907B2/en active Active
-
2020
- 2020-06-29 JP JP2020111574A patent/JP2020152738A/ja active Pending
- 2020-10-26 US US17/080,471 patent/US11690821B2/en active Active
-
2023
- 2023-05-18 US US18/320,159 patent/US12594256B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3209289A1 (en) | 2017-08-30 |
| US20180177756A1 (en) | 2018-06-28 |
| US12594256B2 (en) | 2026-04-07 |
| US20230301961A1 (en) | 2023-09-28 |
| JP2017531043A (ja) | 2017-10-19 |
| EP3209289A4 (en) | 2018-04-11 |
| US11690821B2 (en) | 2023-07-04 |
| CA2964520A1 (en) | 2016-04-28 |
| US20200038365A1 (en) | 2020-02-06 |
| US10441563B2 (en) | 2019-10-15 |
| US10813907B2 (en) | 2020-10-27 |
| JP2020152738A (ja) | 2020-09-24 |
| WO2016064711A1 (en) | 2016-04-28 |
| US20210046038A1 (en) | 2021-02-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12594256B2 (en) | A19-144, A2-73 and certain anticholinesterase inhibitor compositions and method for anti-seizure therapy | |
| Trinka et al. | Pharmacotherapy for status epilepticus | |
| US9750746B2 (en) | ANAVEX2-73 and certain anticholinesterase inhibitors composition and method for neuroprotection | |
| US9750747B2 (en) | Treatments involving eslicarbazepine acetate or eslicarbazepine | |
| Morgan et al. | Drug-induced tremors | |
| AU2011234225B2 (en) | Use of the phytocannabinoid cannabidivarin (CBDV) in the treatment of epilepsy | |
| JP2019536788A (ja) | Ｔ型カルシウムチャンネルブロッカーを含有する薬学的合剤 | |
| RU2268725C2 (ru) | Комбинация лекарственных препаратов, включающая миртазапин, для лечения депрессии и связанных расстройств | |
| RU2351338C2 (ru) | Применение производных карбамазепина для лечения возбуждения у пациентов, страдающих деменцией | |
| Ghaffarpour et al. | Pharmacokinetic and pharmacodynamic properties of the new AEDs: A review article | |
| Longo et al. | Treatment of insomnia in substance abusing patients | |
| WO2008112238A1 (en) | 2, 8-dimethyl-5- [2- (6-methylpyridin-3-yl) -ethyl] -2,3,4, 5-tetrahydro- ih- pyrido [4, 3 -b] indole dihydrochloride (dimebon) for the treatment of chronic pain | |
| US9877951B2 (en) | Method for treating dementia | |
| Rosenhagen et al. | Ketamine’s Evolving Role in Addressing Treatment Resistant Depression | |
| Khan et al. | Extended release quetiapine fumarate (Quetiapine XR) as adjunct therapy in patients with generalized anxiety disorder and a history of inadequate treatment response: a randomized, double-blind study | |
| RU2417085C2 (ru) | Эсликарбазепина ацетат и способы его применения | |
| Benoliel et al. | Pharmacotherapy of chronic orofacial pain | |
| Bondarenko | Experience in the use of the anticonvulsant pregabalin as an add-on therapy in patients with partial epilepsy with polymorphic seizures | |
| Moretti et al. | Lamotrigine as an effective treatment for behavioral disorders | |
| WO2018177693A1 (en) | Sulphated disaccharides for the treatment of neuropathic pain | |
| HK1090543B (en) | Use of carbamazepine derivatives for the treatment of agitation in dementia patients | |
| CA2908706A1 (en) | Treatments involving eslicarbazepine or eslicarbazepine acetate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20201016 |